Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Indian Sun's generic AD drug

The US FDA has approved Indian company Sun Pharma's generic equivalent of Forest Laboratory's Alzheimer's disease treatment Namenda 

The US Food and Drug Administration (FDA) has approved Indian company Sun Pharma's Abbreviated New Drug Application (ANDA) to market a generic equivalent of Forest Laboratory's Alzheimer's disease (AD) treatment Namenda (memantine). Sun will receive 180 days of sales exclusivity on the drug which will be sold in 5mg and 10mg tablets.

The Mumbai-based company said that 5mg and 10mg strengths of memantine have combined annual sales of around $1.2bn in the US.

Memantine is the first in a novel class of Alzheimer's disease medications, which work by acting on the glutamatergic system, blocking NMDA glutamate receptors.

Memantine is also sold by Merz as Akatinol, by Lundbeck as Ebixa and Abixa and by Unipharm as Memox.

6th May 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....